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ABSTRACT  
Background: Genetic disorders causing dystonia show great heterogeneity. Recent studies 
have suggested that next-generation sequencing techniques, such as gene panel analysis, can 
be effective in diagnosing heterogeneous conditions.  
Objectives: We investigated whether dystonia patients with a suspected genetic cause could 
benefit from the use of gene panel analysis.  
Methods: In this post-hoc study, we describe  gene panel analysis results of 61 dystonia 
patients (mean age 31 years, 72% young-onset) in our tertiary referral centre. The panel 
covered 94 dystonia-associated genes. As comparison with a historic cohort was not possible 
due to the rapidly growing list of dystonia genes, we compared the diagnostic work-up with 
and without gene panel analysis in the same patients. The work-up without gene panel 
analysis (control group) included theoretical diagnostic strategies formulated by independent 
experts in the field, based on detailed case descriptions. The primary outcome measure was 
diagnostic yield, secondary measures were cost and duration of diagnostic work-up. 
Results: Work-up with gene panel analysis led to a confirmed molecular diagnosis in 14.8%, 
versus 7.4% in the control group (p=0.096). In the control group on average 3 genes/case 
were requested. The mean costs were lower in the gene panel analysis group (€1822/case) 
than in the controls (€2660/case). The duration of work-up was considerably shorter with 
gene panel analysis (28 vs 102 days). 
Conclusion: Gene panel analysis facilitates molecular diagnosis in complex cases of 
dystonia, with a good diagnostic yield (14.8%), a quicker diagnostic work-up, and lower 
costs, representing a major improvement for patients and their families. 
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INTRODUCTION  
Dystonia is a movement disorder characterized by sustained or intermittent muscle 
contractions causing abnormal, often repetitive, movements or postures, or both. Dystonic 
movements are typically patterned, twisting, and may be tremulous. They are often initiated 
or worsened by voluntary action and associated with overflow muscle activation.1 The 
clinical evaluation of a patient with dystonia is a stepwise process, beginning with 
classification of the dystonia characteristics according to the latest consensus criteria and 
recognition of the dystonia syndrome; this, in turn, may lead to a targeted etiological 
differential diagnosis.2 
 There is a long list of causes of dystonia,3,4 while clinical clues for a genetic form 
include a positive family history and young-onset in the absence of an acquired cause.5 A 
complex clinical picture comprising both neurological and non-neurological features is 
considered to be an important clue for an inborn error of metabolism.6  
The genetic disorders associated with dystonia are often clinically heterogeneous, 
with milder or atypical phenotypes that may easily remain unrecognized. The diagnostic 
work‐up of dystonia can therefore be challenging and time-consuming, and poses a burden on 
patients and their families. 
 It has become possible to analyse thousands of genes simultaneously, since next 
generation sequencing (NGS) techniques were introduced into clinical diagnostics.6,7 Several 
studies suggest that NGS diagnostic strategies can be particularly effective in diagnosing 
heterogeneous conditions, including movement disorders.8-11 One of these NGS techniques is 
targeted gene panel analysis (GPA), which comprises testing a preselected list (or panel) of 
genes causing dystonia. Compared to other NGS techniques, such as whole genome- and 
whole exome sequencing, the cost of GPA is lower and it provides a higher coverage and 
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fewer unsolicited findings. GPA is therefore a good strategy to scan panels of multiple 
candidate genes and it is especially suitable for diagnostic purposes.11,12 
Despite a strong tendency to advocate the advantages of NGS testing, there is no 
evidence as yet that NGS approaches perform better than conventional diagnostic strategies 
for dystonic patients in clinical practice. In cases with an easily recognizable, classical 
phenotype, NGS techniques have limited added value so single gene testing is 
recommended.9 However, in many dystonia cases in which several potentially causal genes 
are being considered, it is hypothesized that NGS strategies hold advantages like an earlier 
diagnosis, a higher diagnostic yield and lower costs.9,11 
 This study therefore aimed to determine the possible benefits of using GPA for 
dystonia patients with a suspected genetic cause compared to conventional diagnostic work-
up.  
 
MATERIALS AND METHODS 
 
Patients 
All patients in this study were referred to the tertiary Movement Disorders outpatient clinic of 
the University Medical Centre Groningen (the Netherlands), to establish the cause of their 
dystonia. In 2013 we introduced GPA of 94 dystonia-associated genes (Supplement 1) as part 
of routine clinical DNA diagnostic testing. Patients of all ages were consecutively enrolled in 
our study if they had isolated dystonia or dystonia as a main symptom, a clinical suspicion of 
a genetic cause, and genetic testing using GPA that was performed between December 2013 
and April 2015. Clinical suspicion of a genetic cause was defined as: absence of clinical clues 
suggesting an acquired cause of dystonia,5 in combination with one or more of the following: 
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onset of dystonia before the age of 40 years; a positive family history; dystonia combined 
with another movement disorder; co-occurrence of other unexplained neurological or 
systemic manifestations; paroxysmal dystonia; laryngeal dystonia (also known as “spasmodic 
dysphonia”). Exclusion criteria were an acquired form of dystonia, no clinical suspicion of a 
genetic cause and dystonia as a minor feature. 
 Of the 61 patients enrolled, 28 (46%) were male. Their mean age was 31.0 years (SD 
21.8, range 1-73 years) on their first visit to our clinic. 44 (72%) of the patients had young-
onset dystonia (starting before age 21 years). The patients’ characteristics are summarized in 
Table 1 and an overview of the clinical characteristics of each individual patient is provided 
in Supplement 2. 
 
Gene panel analysis 
The genes included in the dystonia GPA (Supplement 1) were selected based on a systematic 
literature review.5 From the list of all genes associated with dystonia, genes reported only in 
single families/cases were not put on the diagnostic panel, this to reduce the potential number 
of variants needed to be interpreted by genome staff. Therefore, the unconfirmed candidate 
genes CACNA1B and CIZ1 were omitted from the list. Notably, the list of 94 genes of the 
gene panel excludes several dystonia-associated genes (for example the spinocerebellar 
ataxias genes) because GPA cannot detect repeat expansions, whole exon duplications or 
deletions. 
GPA was offered to patients as a clinical diagnostic test, validated by the standards of 
the Dutch Society for Clinical Genetic Laboratory Diagnostics13. Also the interpretation and 
letters reporting test results were based on these guidelines. All test results, including 
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pathogenic variants and variants of unknown significance, were first discussed in a 
multidisciplinary meeting with neurologists, clinical geneticists and genome laboratory staff. 
When the clinicians stated that a variant of unknown significance in a gene could explain the 
clinical phenotype, additional diagnostics steps were undertaken, such as array-comparative 
genomic hybridization (array-CGH), multiplex ligation-dependent probe amplification 
(MLPA) analysis for autosomal recessive disorders, or sequencing the DNA of the parents to 
detect de-novo variants for dominant disorders. In some cases biochemical testing was done 
to confirm a diagnosis. 
 
Study Design 
We conducted a post-hoc analysis by comparing the GPA study group to a theoretical control 
group without GPA. The primary outcome was the diagnostic yield and secondary outcomes 
were the cost and duration of diagnostic work-up. 
 As comparison with a historic cohort was not possible due to the rapidly growing list 
of dystonia genes, we compared the diagnostic work-up with and without GPA in the same 
patients. Each patient in our study therefore served as his/her own control. We built up a 
theoretical situation in which independent experts in the field were twice asked to formulate a 
diagnostic strategy: first based only on the detailed clinical case description (Part 1), and 
secondly after we incorporated the results of further additional tests, like laboratory 
investigations and neuroimaging findings, except for the results of GPA (Part 2).  
 The diagnostic yield obtained in the controls after Part 2 was compared to the 
diagnostic yield obtained for the patients after GPA. The cost and duration of the diagnostic 
strategy for the controls in Part 1 were compared to the cost and time required to perform the 
dystonia GPA. These study methods will be discussed in more detail below. Figure 1 gives an 
overview of the study design.  
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Diagnostic evaluation with GPA  
For the diagnostic work-up in the study group we followed our reported algorithm.5 None of 
our 61 cases had any clinical clues of an acquired form of dystonia, neither in their clinical 
presentation nor on brain MRI. Biochemical diagnostics and a levodopa trial,5 were not 
included in the diagnostic work-up in the study group, as GPA is quicker in our centre (28 
days). Therefore, the diagnostic work-up in the study group consisted exclusively of GPA.  
  
Diagnostic evaluation without GPA 
For each case, we had a description of the clinical phenotype (comprising the patient’s 
medical history, history of present illness, family history, medication use, the physical and 
neurological examination findings, and the results of the brain MRI). All case descriptions 
were reviewed by the treating physician to ensure they presented an accurate reflection of the 
clinical picture.  
 We asked eight independent international experts to take part in our study (4 
neurologists and 4 paediatric neurologists). Each case description was anonymised and 
randomly sent to two experts, who independently assessed the cases. We took into account 
the age of the patient at the time of examination when sending the cases to the paediatric or 
adult neurologists, using the age of 18 as cut-off point.  
Each case would be independently assessed by two experts, and inevitably, both 
experts would have differences in their assessments. Therefore, we decided to consider each 
assessment separately, resulting in a control group of 122 assessments. 
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 In Part 1 (control group), the experts formulated their theoretical diagnostic work-up 
and diagnostic guess. The experts could request any additional tests they deemed necessary, 
including a levodopa trial and single gene testing, but they were not allowed to use any NGS 
techniques in their diagnostic work-up. In Part 2 the case descriptions were again given to the 
same expert, but now with the results of all the additional tests (serum, urine, cerebrospinal 
fluid (CSF) analysis, muscle and skin biopsies, consultations with other medical specialists, 
neuroimaging, neurophysiological tests, and the levodopa trial if available), all this 
information was retrieved from the patients’ medical records. However, the results of the 
dystonia GPA were not provided.  
 After Part 2, the two experts reported their theoretical diagnostic strategies and 
diagnostic guess, again independently. They could request any extra tests deemed necessary, 
except for NGS techniques.  
 
Outcome measures 
We defined the diagnostic yield as the percentage of cases with a genetically confirmed 
diagnosis. The diagnostic yield of the dystonia GPA in the 61 cases of the study group was 
compared to the diagnostic yield of the 122 theoretical diagnostic strategies in the control 
group. The diagnostic yield of the control group without GPA was established by assessing 
whether the single gene testing requested by the experts would have led to the etiological 
diagnosis according to the results of the dystonia GPA. 
 We investigated the cost of performing the dystonia GPA at our centre (study group), 
and also the cost of performing the diagnostic tests requested by the experts for the controls 
in Part 1 (see Supplement 3).  
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To establish the duration of the diagnostic work-up, we used standard reporting times 
for the diagnostic procedures in our clinic (see Supplement 3). In the study group, we defined 
the duration of diagnostic work-up as the time between requesting the dystonia GPA  and 
receiving the results. In the control group (Part 1), we determined the theoretical cost and 
theoretical duration of diagnostic work-up based on the experts’ proposed strategies. To 
establish the duration, we considered the sequence of tests requested (simultaneous tests 
versus sequential tests).When an expert requested multiple simultaneous tests, only the test 
with the longest duration to generate a diagnostic report was taken into account. If the 
expert’s strategy would have led to an etiological diagnosis halfway through the theoretical 
procedure the cost and time-frame of the remaining tests were not used in the analysis. 
 The use of brain MRI was not taken into account in analysing both the study and 
control groups, because we considered the MRI to be an indispensable part of both the 
conventional diagnostic work-up (control group) and of the work-up with GPA (study 
group).2,5 Therefore, the results of brain MRI were included in the clinical case descriptions 
in Part 1. 
 
Statistical analysis 
We used SPSS (version 22, IBM SPSS Statistics) for our analysis and the one-sided Fisher’s 
Exact Test (α=0.05) for our primary outcome. For the secondary outcomes, we described the 
mean and range of the cost and duration of the diagnostic work-up, with and without GPA. 
Comparison with Fisher’s Exact test was not possible for the secondary outcomes because of 
the fixed cost and fixed duration of GPA.  
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RESULTS 
Study group: diagnostic work-up with GPA  
In a multidisciplinary meeting with neurologists, clinical geneticists and genome laboratory 
staff all GPA results were discussed, including pathogenic variants and variants of unknown 
significance. Population frequencies and conflicting data regarding specific variants known in 
the literature were taken into consideration. In the series of patients included in this study, on 
average 0 to 2 variants of unknown significance were detected, and all were considered very 
unlikely to explain the phenotype. Therefore additional diagnostic steps, such array-CGH or 
MLPA analysis, were felt unnecessary.  
In the study group a genetically confirmed cause of the dystonia was determined in 
9/61 patients (14.8%). The following diagnoses were made: DYT16 (PRKRA gene), Segawa 
syndrome (TH gene), glutaric aciduria type I (GCDH gene), Niemann-Pick type C (NPC1 
gene), paroxysmal kinesigenic dyskinesia (PRRT2 gene) in three patients, and Rett syndrome 
(MECP2 gene) in two patients (Table 2). 
 
Control group: diagnostic work-up without GPA 
For the 122 control case descriptions, there was a total of 355 requests for gene tests on 66 
different genes. On average, 3 single gene tests per case were requested by the experts. These 
led to identification of the genetic cause of the dystonia in 9/122 assessments (7.4%), see 
Table 2. 
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Diagnostic Yield 
The genetic diagnostic yield in the study group with GPA (14.8%) was higher than in the 
controls without GPA (7.4%), with statistical analysis tending towards, but not reaching, 
levels of significance (p=0.096).  
 
Cost and duration of diagnosic work-up 
The cost of performing the dystonia GPA for one patient was €1,822 (study group). An 
overview of the requested diagnostic tests in the control group is shown in Supplement 3. The 
sum total of cost of the diagnostic strategies in the controls was € 324,482.93, which was 
divided by 122, resulting in a mean cost for the diagnostic tests in the controls of €2,660 per 
patient (SD 2747, range €0 to €18,688). For an overview of the requested tests in the control 
group, see Supplement 3.  
We performed a sub-analysis to compare the cost of the diagnostic work-up using 
only single gene testing in the control group, with the cost of GPA. The cost of the work-up 
with single gene testing alone was € 2,238 per patient (SD 2,444, range €0 to €16,918), which 
is higher than the cost of GPA (€1,822 per patient). 
 For the study group, the timeframe between requesting the dystonia GPA and 
receiving the results was 28 days. The mean duration of the diagnostic work-up in the 
controls was 102 days (SD 66 days, range 0-301 days).  
The lower limit of the range of zero for cost and duration of the diagnostic work-up in 
the control group was based one case where one of the experts decided not to do any 
additional testing because of a presumed stationary encephalopathy.   
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DISCUSSION 
This study shows that GPA facilitates molecular diagnosis in complex cases of dystonia, with 
a good diagnostic yield (14.8%), a quicker diagnostic work-up, and lower costs.  
In an ideal situation we would have set up a prospective cohort study, however, in 
such a study design it would not be ethically justified to withhold the use of NGS diagnostics 
to patients in the control group. We considered using a historic control group, but using a 
historic cohort of dystonia patients would not be relevant, as the list of known dystonia genes 
has expanded rapidly. Therefore, we compared the diagnostic work-up with and without GPA 
in the same patients: each patient in our study served as his/her own control. The study design 
reflects a pragmatic approach: we evaluated how dystonia diagnostics are performed in 
clinical practice, with the aim of helping clinicians to make an informed choice between the 
conventional diagnostic work-up and a work-up with GPA.  
The use of GPA in dystonia diagnostics in this study increased the yield compared to 
conventional work-up, with statistical analysis tending towards, but not reaching, levels of 
significance. This may be due to the relatively small group of patients.  
Looking more closely at our results, we saw that particularly patients with an unusual 
or complex phenotype benefitted from GPA, with disorders not considered in the initial 
differential diagnosis being identified. Below, we highlight three examples from our study. 
First, a patient who presented at the age of 44 years in whom GPA analysis 
demonstrated a GCDH gene mutation (glutaric acidemia type I). Second, a patient with adult-
onset myoclonus who later developed dystonia in his sixties and proved to have Niemann-
Pick type C disease. And third, a patient with motor developmental delay as a child, who 
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developed rapidly progressive parkinsonism and multifocal dystonia at age 13, and was then 
found to have a TH (Tyrosine Hydroxylase) gene mutation. Importantly, all three disorders 
are treatable forms of inborn errors of metabolism, with an accurate diagnosis allowing 
prompt initiation of therapy. Our findings are in line with other studies that suggest that 
particularly patients with a non-specific or atypical clinical presentation will most likely 
benefit from NGS diagnostics.9-11  
 To our knowledge, this is the first study comparing the diagnostic yield of NGS 
techniques to conventional genetic techniques in diagnosing patients with dystonia, although 
other studies have compared NGS techniques to conventional genetic testing in other 
disorders, including movement disorders.8,9  
Neveling and colleagues compared whole exome sequencing (WES) to Sanger 
sequencing in patients with heterogeneous diseases, including movement disorders.8 The use 
of WES in 50 patients with movement disorders (29 hereditary spastic paraplegia, 12 
cerebellar ataxia, 9 dystonia) compared to Sanger sequencing in 953 patients with movement 
disorders: WES had a diagnostic yield of 20% versus 5% in the Sanger sequencing group. 
The diagnostic yield of NGS in movement disorders in the study of Neveling et al. is higher 
(20%) than in our study (14%). This can be explained by differences in the patient population 
tested and a different study design, but another reason may lie in the fact that GPA is 
restricted to preselected genes only, in contrast to WES. However, when we designed our 
study, we opted for GPA as the genetic coverage (sequencing depth) was higher than with 
other forms of NGS, at lower cost and with fewer variants to be interpreted and unsolicited 
findings.  
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Notably, the patients included in our study were all tertiary referrals and 16 (26%) of 
them were referred to us from other tertiary centres (Table 1). As a consequence, our study 
population comprised many complex cases, which is reflected in the proportion of cases that 
remained undiagnosed even after GPA. This is in line with other GPA studies with highly 
selected patient populations.12,16 
In heterogeneous disorders where several potential genes are considered, the 
hypothesized advantages of NGS strategies are not only a higher diagnostic yield, but also an 
earlier diagnosis and lower costs. However, there is little published data relating to the cost-
effectiveness of NGS technologies to date.17,18 
In our study, the mean costs were lower in the GPA group (€1822/case) than in the 
controls (€2660/case), and the cost incurred per expert varied greatly (range €0 to over 
€18,988). This illustrates the very different diagnostic strategies used by individual experts. 
One possible explanation is the variability in costs, budgets and availability of diagnostic 
procedures between centres and countries, leading to different daily routines of clinicians. 
The cases with the highest costs were those with the most complex phenotypes, in which the 
cost-effectiveness of GPA can be highest. This is consistent with the cost-effectiveness of 
WES recently demonstrated in complex cases in a paediatric cohort with heterogeneous 
disorders.18 
 The duration of the diagnostic work-up with GPA was considerably shorter than the 
mean duration of the conventional work-up in the control group (28 vs 102 days). The 
duration in the control group is likely to be underestimated, as there is usually a delay in 
clinical practice between receiving the results of investigations, obtaining patient consent for 
the next diagnostic test, and requesting the next test. Furthermore, it has been shown in other 
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studies that the diagnostic work-up for dystonia patients may require many years.5,19 The 
reason for the relatively short duration of the diagnostic work-up in the control group of our 
study is probably the involvement of highly experienced dystonia experts. A quicker 
diagnostic work-up in the GPA group compared to conventional is a relevant finding, because 
the diagnostic odyssey is costly both in terms of health care resources and poses a burden on 
the patient and his/her family.20 In addition, diagnostic delays can have major implications 
with regard to potential therapies and avoiding unnecessary investigations.  
 In conclusion, our results show that GPA facilitates molecular diagnosis in complex 
cases of dystonia, with a good diagnostic yield, a quicker diagnostic work-up, and lower 
costs, representing a major improvement for patients and their families. However, as 
Hennekam and Biesecker clearly stated, NGS and computers will not magically make 
diagnoses for us.21 Careful clinical evaluation of the patient remains fundamental and NGS 
should not replace deep clinical phenotyping. As evident from our study, Sanger sequencing 
of the candidate gene will often lead to a diagnosis in cases with a classical phenotype. Ìn 
patients with complex and unusual phenotypes careful clinical evaluation remains important 
as ever, however, in these cases there will be a shift from a pre-NGS-test differential 
diagnostic mode to a post-NGS-test diagnostic assessment mode.21 In line with this, a user-
friendly and expandable online tool has been developed to help movement disorder clinicians 
to link NGS-test results to the clinical and phenotypic data of the individual patient.22 
In the near future, NGS techniques will become increasingly incorporated into our 
daily clinical routines. Here we choose to use a targeted gene panel analysis, but WES 
coverage has improved significantly over time at much lower costs, making it more 
accessible for routine diagnostic purposes. With these advances in WES it will become easier 
to keep diagnostic tests up-to-date to the rapid expanding lists of genes associated with 
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dystonia, but also to have the possibility to unravel novel dystonia associated genes. For 
heterogeneous disorders, such as dystonia, these developments will lead to earlier etiological 
diagnosis in a higher proportion of cases. 
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Legend to Figure 1 
Study design scheme, 61 cases were included. Descriptions were made based on the patients’ 
medical records. Two independent experts assessed the cases on their clinical features and 
developed a theoretical diagnostic strategy for each case (Part 1). They could request any 
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extra tests deemed necessary, except for next-generation sequencing techniques. In Part 2 the 
cases were supplemented with the results of additional investigations and reassessed by the 
experts. 
 
Supplement 1. Dystonia gene panel (94 dystonia-related genes) 
 
 
Gene (OMIM) 
 
Disease name/phenotype 
 
Mode of inheritance 
 
 
ADAR (146920) 
 
Aicardi-Goutieres syndrome 6 
 
AR, AD 
 
ADCY5 (600293) 
 
Familial dyskinesia with facial 
myokymia 
 
AD 
 
ALDH5A1 (610045) 
 
Succinic semialdehyde dehydrogenase 
deficiency 
 
AR 
 
ANO3 (610110) 
 
DYT24: isolated focal dystonia 
 
AD 
 
ARX (300382) 
 
Partington syndrome/X-linked mental 
retardation 
 
XR 
 
ATP13A2 (610513) 
 
Kufor-Rakeb syndrome (PARK9) 
 
AR 
 
ATP1A3 (182350) 
 
DYT12: Rapid-onset dystonia 
parkinsonism 
 
AD 
 
ATP7B (606882) 
 
Wilson’s disease 
 
AR 
 
BCS1L (603647) 
 
Mitochondrial complex III 
deficiency/Leigh syndrome 
 
AR 
 
C10ORF2 (609286) 
 
Progressive external ophtalmoplegia 
with mitochondrial DNA deletions 
 
AD 
 
C19orf12 (614297) 
 
Neurodegeneration with brain iron 
accumulation (NBIA) 4 
 
AR 
 
CDKL5  (300203) 
 
Early-onset epileptic encephalopathy / 
variant Rett syndrome 
 
XD 
 
COX10 (602125) 
 
Mitochondrial complex IV 
deficiency/Leigh syndrome 
 
AR 
 
COX15 (603646) 
 
Mitochondrial complex IV 
deficiency/Leigh syndrome 
 
AR 
 
COX20 (614698) 
 
Mitochondrial complex IV deficiency 
 
AR 
 
CP (117700) 
 
Aceruloplasminemia 
 
AR 
 
DDC (107930) 
 
Aromatic L-amino acid decarboxylase 
deficiency 
 
AR 
 DJ1 (602533) 
 
Early onset Parkinson disease type 7 
(PARK7) 
 
AR 
 
DLAT (608770) 
 
Pyruvate dehydrogenase E2 deficiency 
 
AR 
 
DLD (238331) 
 
Dihydrolipoamide dehydrogenase 
deficiency (Maple syrup urine disease 
type III) 
 
AR 
 
FA2H (611026) 
 
Spastic paraplegia type 35 
 
AR 
 
FBXO7 (605648) 
 
 
Early onset Parkinson disease type 15 
(PARK15) 
 
AR 
 
 
FOLR1 (136430) 
 
Cerebral folate deficiency 
 
AR 
 
FOXG1 (164874) 
 
Rett syndrome, congenital variant 
 
de novo 
 
FTL (134790) 
 
Neurodegeneration with brain iron 
accumulation (NBIA) 3 
 
AD 
 
FUS (137070) 
 
Hereditary essential tremor (ETM4) 
 
AD 
 
GCDH (608801) 
 
Glutaric aciduria type 1 
 
AR 
 
GCH1 (600225) 
 
DYT5: GTP-cyclohydrolase 1 
deficiency 
 
AD 
 
GNAL (139312) 
 
DYT25: isolated dystonia 
 
AD 
 
LRPPRC (607544) 
 
Leigh syndrome, French-Canadian type 
 
AR 
 
MECP2 (300005) 
 
Rett syndrome 
 
XD 
 
MTTP (157147) 
 
Abetalipoproteinemia 
 
AR 
 
NDUFA10 (603835) 
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
AR 
 
NDUFA12 (614530) 
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
AR 
 
NDUFA2 (602137) 
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
AR 
 
NDUFA9 (603834) 
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
AR 
 
NDUFAF2 (609653) 
  
AR 
3 
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
NDUFAF5 (612360) 
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
AR 
 
NDUFAF6 (C8orf38)  
(612392) 
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
AR 
 
NDUFS1 (157655) 
 
Mitochondrial complex I deficiency 
 
AR 
 
NDUFS3 (603846) 
 
Mitochondrial complex I deficiency 
 
AR 
 
NDUFS4 (602694)  
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
AR 
 
NDUFS7 (601825) 
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
AR 
 
NDUFS8 (602141) 
 
Mitochondrial complex I 
deficiency/Leigh syndrome 
 
AR 
 
NKX2-1/TITF1 
(600635) 
 
Benign hereditary chorea 
 
AD 
 
NPC1 (607623) 
 
Niemann Pick type C 
 
AR 
 
NPC2 (601015) 
 
Niemann Pick type C 
 
AR 
 
NUP62 (605815) 
 
Infantile striatonigral degeneration 
 
AR 
 
PAH (612349) 
 
Phenylketonuria/hyperphenylalaninemia 
  
AR 
 
PANK2 (606157) 
 
Neurodegeneration with brain iron 
accumulation (NBIA) 1/HARP 
 
AR 
 
PRKN (602544) 
 
Juvenile Parkinson disease type 2 
(PARK2) 
 
AR 
 
PCBD1 (126090) 
 
Hyperphenylalaninemia variant D 
 
AR 
 
PDHA1 (300502) 
 
Pyruvate dehydrogenase E1-alpha 
deficiency 
 
XD 
 
PDHB (179060) 
 
Pyruvate dehydrogenase E1-beta 
deficiency 
 
AR 
 
PDHX (608769) 
 
Pyruvate dehydrogenase E3-binding 
protein deficiency 
 
AR 
 PINK1 (608309) 
 
Early onset Parkinson disease type 6 
(PARK6) 
 
AR 
 
PLA2G6 (603604) 
 
Neurodegeneration with brain iron 
accumulation (NBIA) 2/PARK14 
 
AR 
 
PLP1 (300401) 
 
Pelizaeus-Merzbacher disease 
 
XR 
 
PNKD/MR1 (609023) 
 
DYT8: Paroxysmal non-kinesigenic 
dyskinesia 
 
AD 
 
POLG (174763) 
 
Alpers/MNGIE/SANDO (Mitochondrial 
DNA depletion syndrome 4) 
 
AR 
 
PRKRA (603424) 
 
DYT16: Young-onset dystonia 
parkinsonism 
 
AR 
 
PRRT2 (614386) 
 
DYT10: Paroxysmal kinesigenic 
dyskinesia 
 
AD 
 
PTS (612719) 
 
6-Pyruvoyltetra-hydropterin synthase 
(PTPS) deficiency 
 
AR 
 
QDPR (612676) 
 
Dihydropteridine reductase  
(DHPR) deficiency  
 
AR 
 
RNASEH2A (606034) 
 
Aicardi-Goutieres syndrome 4 
 
AR 
 
RNASEH2B (610362) 
 
Aicardi-Goutieres syndrome 2 
 
AR 
 
RNASEH2C (610330) 
 
Aicardi-Goutieres syndrome 3 
 
AR 
 
SAMHD1 (606754) 
 
Aicardi-Goutieres syndrome 5 
 
AR 
 
SCO2 (604272) 
 
Cardioencephalomyopathy due to 
cytochrome c oxidase deficiency 1 
 
AR 
 
SERAC1 (614725) 
 
3-methylglutaconic aciduria with 
deafness, encephalopathy, and Leigh-
like syndrome (MEGDEL) 
 
AR 
 
SGCE (604149) 
 
DYT11: Myoclonus-dystonia 
 
AD 
 
SLC16A2 (300095) 
 
Allan-Herndon-Dudley syndrome 
(monocarboxylate transporter-8 (MCT8) 
deficiency) 
 
XD 
 
SLC19A3 (606152) 
  
AR 
5 
 
Thiamine transporter deficiency 
(formerly Biotin responsive basal 
ganglia disorder) 
 
SLC20A1 (137570) 
 
Familial idiopathic basal ganglia 
calcification 
 
AD 
 
SLC2A1 (138140) 
 
DYT9/18: Paroxysmal choreoathetosis 
with episodic ataxia and 
spasticity/GLUT1 deficiency syndrome-
1 
 
AD 
 
SLC30A10 (611146) 
 
Dystonia with brain manganese 
accumulation  
 
AR 
 
SLC6A19 (608893) 
 
Hartnup disease 
 
AR 
 
SLC6A3 (126455) 
 
Infantile parkinsonism-dystonia 
(Dopamine transporter deficiency) 
 
AR 
 
SPG11 (610844) 
 
Spastic paraplegia type 11 
 
AR 
 
SPG7 (602783) 
 
Spastic paraplegia type 7 
 
AR 
 
SPR (182125) 
 
Sepiaterine reductase deficiency 
 
AR 
 
SUCLA2 (603921) 
 
Mitochondrial DNA depletion syndrome 
5 
 
AR 
 
SUCLG1 (611224) 
 
 
Mitochondrial DNA depletion syndrome 
9 
 
AR 
 
SURF1 (185620) 
 
Mitochondrial complex IV 
deficiency/Leigh syndrome 
 
AR 
 
TACO1 (612958) 
 
Mitochondrial complex IV 
deficiency/Leigh syndrome 
 
AR 
 
TAF1 (313650) 
 
DYT3:  X-linked dystonia-parkinsonism 
 
XR 
 
TH (191290) 
 
Tyrosine hydroxylase deficiency 
 
AR 
 
THAP1 (609520) 
 
DYT6: Adolescent onset torsion 
dystonia, mixed type 
 
AD 
 
TIMM8A (300356) 
 
 
Mohr-Tranebjaerg syndrome (Dystonia 
deafness syndrome) 
 
XR 
 
  
TOR1A (605204) 
  
AD 
DYT1: Early-onset generalized isolated 
dystonia (PTD) 
 
TREX1 (606609) 
 
Aicardi-Goutieres syndrome 1 
 
AR, AD 
 
TUBB4A (602662) 
 
DYT4: Whispering dystonia 
 
AD 
 
VPS13A (605978) 
 
Choreoacanthocytosis 
 
AR 
 
Wdr45 (300894) 
 
Neurodegeneration with brain iron 
accumulation (NBIA) 5 
 
 
XD 
 
Note: This list of genes excludes several dystonia-associated genes, for example the 
spinocerebellar ataxias genes, because gene panel analysis cannot detect repeat expansions, 
whole exon duplications or deletions. Furthermore, the ATM gene (ataxia telangiectasia) was 
omitted from the list, after much debate within our multidisciplinary team, given the fact that 
carriers of ATM have an increased risk for breast cancer. Finally, because a limited amount of 
genes that could be included in the panel, the HPRT1 gene (Lesch-Nyhan syndrome) was left 
out, because Lesch-Nyhan syndrome can be easily diagnosed by testing uric acid in plasma, 
saving space in the panel for other genes. However, both ATM and HPRT1 will be included in 
the updated version of the dystonia gene panel that currently is being implemented in our 
centre. 
 
Abbreviations: OMIM, Online Mendelian Inheritance in Man (www.omim.org); AR, 
autosomal recessive; AD, autosomal dominant; XR, X-linked recessive; XD, X-linked 
dominant. 
 
 
Table 1. Patients characteristics 
Age of onset of dystonia Number (%) Age on first visit (SD) Academic referrals* 
 
0-2 years 
 
18 (29.5) 
 
17.5 (±14.8) 
 
6 (33.3) 
3-12 years 17 (27.9) 18.9 (±13.6) 4 (23.5) 
13-20 years 9 (14.7) 34.9 (±19.2) 0 (0.0) 
21-40 years 8 (13.1) 46.4 (±12.2) 2 (25.0) 
>40 years 9 (14.7) 63.3 (±8.8) 4 (44.4) 
 
Overall 
 
61 (100) 
 
31.0 (±21.8) 
 
16 (26.2%) 
 
*Academic referrals: these patients were referred to us from other tertiary centres 
Abbreviation: SD, standard deviation. 
 
Table 2. Identified Genetic Causes 
Case  
no. 
Child (<19y) 
or adult  
Identified 
gene 
Mode of  
inheritance 
Mutation Yield Diagnosed by experts 
(control group) 
1      child PRKRA 
(DYT16) 
AR c.558G>T p.(Glu186Asp ) Suggestive* 1 of 2 
6      adult MECP2 XD c.379C>A p.(Pro127Thr) Solved 1 of 2 
16    adult GCDH# AR c.482G>A p.(Arg161Gln) and  
c.1262C>T p.(Ala421Val) § 
Solved 0 of 2 
17  Child PRRT2 AD c.649dupC Solved 2 of 2 
19 child TH# AR c.1394C>G p.(Ser465Cys) Suggestive* 0 of 2 
27 child MECP2 XD c.1178C>T p. (Pro393Leu) Suggestive* 1 of 2 
32 adult  PRRT2 AD c.649dupC Solved 2 of 2 
37 adult PRRT2 AD c.649dupC  Solved 2 of 2 
50 Adult NPC1# AR c.2474A>G p.(Tyr825Cys) and  
c.3019C>G p.(Pro1007Ala) § 
Solved 0 of 2 
 
Notes: Identified genetic causes: causal genes found in 9/61 patients and in 9/122 of the theoretical cases. Patients 17, 32 and 37 are not related. 
* Suggestive yield means that our multidisciplinary team of clinicians and laboratory staff considered the results of genetic testing highly suggestive for a 
diagnosis, which often was afterwards confirmed by additional biochemical testing and/or molecular investigations of family members.  With regard to case 1: 
the heterozygous mutation was considered causative based on reports of patients with heterozygous mutations in the PRKRA gene with a very similar 
phenotype14, and the patient had an excellent response on pallidal stimulation which is in favor of an isolated dystonia such as DYT16. Concerning case 19: it 
was taken into account that over 10% of TH mutations can be found in the promotor region of the TH gene15, these mutations will not be detected in a gene 
panel strategy. Therefore, in this patient a lumbar puncture was performed showing low homovanillic acid in CSF, confirming the diagnosis of TH deficiency. 
# indicates a treatable inborn error of metabolism 
§ indicates compound heterozygosity 
Abbreviations: AR, autosomal recessive; AD, autosomal dominant; XD, X-linked dominant. 

